-0.13 (-2.17%)
Dilution Risk
Revenue
20.75 M
R&D Expenses
2.33 M
Operating CF
-662.00 K
Total Assets
77.94 M
Total Liabilities
67.89 M
Equity
10.05 M
D/E Ratio
12,345
Cash Position
7.10 M
Monthly Burn
221.00 K
Runway
30.9 mo
Burn Trend
SEC Filing
May 12, 2026locked
| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology |
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Teduglutide Small molecule | HIV | Phase 2 | NCT02431325 | 40% | $3.3B | COMPLETED | 32 | - | - | Jan 21, 2021 | - | Jun 12, 2023 |
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 |
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-08-21 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-08-21 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-08-21 | 0.00 | 0 | - | - | - | - | - | - | ||||
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Harvard Bioscience, Inc. will release its financial results for Q1 2026 on May 12, 2026, before market opening. A conference call will follow at 8:00 AM ET, allowing analysts to inquire about the results. The earnings release and presentation will be accessible on the company's investor relations website.
Read more →Harvard Bioscience reported its fourth quarter and full-year financial results for 2025, revealing revenues of $23.7 million in Q4 and $86.6 million for the year. The company experienced a net loss of $56.7 million, attributed to goodwill impairment and other costs. Looking ahead, Harvard Bioscience introduced guidance for 2026, anticipating revenue growth driven by new product innovations in translational science.
Read more →Harvard Bioscience announced a 1-for-10 reverse stock split approved by shareholders to enhance its stock price and comply with Nasdaq listing requirements. The split will take effect on March 13, 2026, reducing outstanding shares from approximately 44.7 million to about 4.5 million. Shareholders will receive cash for any fractional shares resulting from the split.
Read more →Harvard Bioscience, Inc. announced its participation in KeyBanc Capital Markets' Virtual Healthcare Forum on March 17th. CEO John Duke and Interim CFO Mark Frost will engage in a fireside chat, which will be accessible via the company's investor relations website. This event aims to enhance communication with investors and stakeholders.
Read more →Harvard Bioscience, Inc. will release its financial results for Q4 2025 on March 12, 2026, before the market opens. A conference call will follow at 8:00 AM ET, allowing participants to ask questions after registering. Financial details will be accessible on the company's investor relations website.
Read more →Harvard Bioscience announced preliminary financial results for Q4 2025, showcasing a positive outlook for 2026. The company aims to transition from a traditional tools provider to a leader in Translational Science, focusing on sustainable growth through strategic pillars. CEO John Duke expressed confidence in revenue and EBITDA growth, with detailed results to be released on March 12, 2026.
Read more →Harvard Bioscience announced a strategic consolidation of its manufacturing operations, closing its Holliston, MA facility and transitioning production to Minneapolis, MN, as well as relocating some operations to Europe. This move aims to enhance efficiency and achieve significant cost savings. The consolidation is expected to be completed by Q1 2027, with a comprehensive transition plan in place to ensure continuity.
Read more →Harvard Bioscience has successfully completed a $40 million debt refinancing agreement with BroadOak Capital Partners. This financing includes three term loans aimed at retiring existing debt and improving the company's financial stability. Additionally, Bill Snider from BroadOak has joined the board of directors, further strengthening the company's leadership as it focuses on growth and strategic priorities.
Read more →Harvard Bioscience reported its third quarter 2025 financial results, showing a revenue of $20.6 million, a slight decrease from the previous year. However, the company noted improved customer engagement and a growing backlog, indicating positive momentum. Despite a net loss of $1.2 million, adjusted EBITDA rose to $2.0 million. The company anticipates continued growth in the fourth quarter.
Read more →Harvard Bioscience, Inc. will announce its Q3 2025 financial results on November 6, 2025. The announcement will occur before market opening, followed by a conference call at 8:00 AM ET. Participants can register to ask questions, and financial details will be available on the company's investor relations website.
Read more →Harvard Bioscience has expanded its distribution agreement with Fisher Scientific to include the U.S. market, enhancing access to its products such as pumps and spectrophotometers. This collaboration aims to improve customer experience through streamlined ordering and localized support. The agreement also introduces advanced technologies for organoid research, furthering Harvard Bioscience's commitment to scientific discovery.
Read more →Harvard Bioscience has appointed Stephen DeNelsky to its Board of Directors, effective September 5, 2025. DeNelsky brings 30 years of experience in healthcare equities and will also serve on the Nominating and Governance Committee. His expertise is expected to enhance the company's governance and financial strategy as it seeks to create long-term value.
Read more →Harvard Bioscience announced a CEO succession plan with John Duke set to take over from Jim Green on July 28, 2025. Duke, currently a board member and CEO of PMT, aims to drive growth and profitability. Additionally, Rob Gagnon and Seth Benson have been appointed to the Board of Directors. The company anticipates second-quarter revenue of $20.4 million.
Read more →Harvard Bioscience has appointed John Duke to its board of directors, effective June 2, 2025. Duke, who has a strong background in life science tools and business execution, will also serve on the audit and governance committees. Katherine Eade has been named Lead Independent Director, while Thomas Loewald has retired from the board.
Read more →